AR120727A1 - PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME - Google Patents

PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME

Info

Publication number
AR120727A1
AR120727A1 ARP200103449A ARP200103449A AR120727A1 AR 120727 A1 AR120727 A1 AR 120727A1 AR P200103449 A ARP200103449 A AR P200103449A AR P200103449 A ARP200103449 A AR P200103449A AR 120727 A1 AR120727 A1 AR 120727A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
preparation
same
bpi
comprises bpi
Prior art date
Application number
ARP200103449A
Other languages
Spanish (es)
Inventor
Chengwu Yu
Xin Li
Chun Tang
Xiaoxia Zhang
Jirong Peng
Don Zhang
Yuelie Lu
Original Assignee
Beta Pharma Suzhou Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beta Pharma Suzhou Ltd filed Critical Beta Pharma Suzhou Ltd
Publication of AR120727A1 publication Critical patent/AR120727A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente describe una composición farmacéutica que comprende una sal farmacéuticamente aceptable de un compuesto de la fórmula (1), un diluyente, un disgregante y un lubricante. La composición farmacéutica puede disolverse extremadamente rápido y tiene una elevada biodisponibilidad de la droga y calidad estable. Además, la composición farmacéutica puede ser preparada mediante un método directo de rellenado en polvo, lo cual es adecuado para producción industrial.The present describes a pharmaceutical composition comprising a pharmaceutically acceptable salt of a compound of formula (1), a diluent, a disintegrant and a lubricant. The pharmaceutical composition can dissolve extremely fast and has high drug bioavailability and stable quality. Furthermore, the pharmaceutical composition can be prepared by a direct powder-filling method, which is suitable for industrial production.

ARP200103449A 2019-12-11 2020-12-11 PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME AR120727A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911264353.1A CN110898026A (en) 2019-12-11 2019-12-11 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Publications (1)

Publication Number Publication Date
AR120727A1 true AR120727A1 (en) 2022-03-09

Family

ID=69824307

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200103449A AR120727A1 (en) 2019-12-11 2020-12-11 PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME

Country Status (4)

Country Link
CN (1) CN110898026A (en)
AR (1) AR120727A1 (en)
TW (1) TW202122087A (en)
WO (1) WO2021115425A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110898026A (en) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111170998B (en) * 2014-11-05 2023-04-11 益方生物科技(上海)股份有限公司 Pyrimidine or pyridine compound, preparation method and medical application thereof
CA3027732A1 (en) * 2016-06-17 2017-12-21 Beta Pharma, Inc. Pharmaceutical salts of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and crystalline forms thereof
BR112019026483A2 (en) * 2017-06-16 2020-07-14 Beta Pharma, Inc. pharmaceutical formulation of n- (2- (2- (dimethylamine) ethoxy) -4-methoxy-5 - ((4- (1-methyl-1h-indol-3-yl) pyrimidin-2-yl) amine) phenyl) acrylamide and its salts
CN110898026A (en) * 2019-12-11 2020-03-24 倍而达药业（苏州）有限公司 Pharmaceutical composition containing BPI-7711 and preparation method thereof

Also Published As

Publication number Publication date
WO2021115425A1 (en) 2021-06-17
CN110898026A (en) 2020-03-24
TW202122087A (en) 2021-06-16

Similar Documents

Publication Publication Date Title
JOP20220155A1 (en) Pyrazolyl derivatives useful as anti-cancer agents
MX2020000268A (en) Fxr receptor agonist.
PH12018502227A1 (en) Macrocyclic mcl1 inhibitors for treating cancer
MX2022008066A (en) Substituted tricyclic compounds.
MX2022006475A (en) Substituted tricyclic compounds.
EA201201496A1 (en) A method of inhibiting HIV integrase, METHOD FOR IMPROVED PHARMACOKINETICS 6- (3-chloro-2-fluorobenzyl) -1 - [(2S) -1-Hydroxy-3-methylbutan-2-yl] -7-methoxy-4-oxo-1 4-DIHYDROCHINOLIN-3-CARBONIC ACID (OPTIONS), SET, PHARMACEUTICAL COMPOSITION (OPTIONS) AND ANTIRETROVIRAL AGENT (OPTIONS)
MX2020002696A (en) Bisamide sarcomere activating compounds and uses thereof.
MX2022001784A (en) Piperidinyl-methyl-purineamines as nsd2 inhibitors and anti-cancer agents.
MX2020009530A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glycopyranosidase inhibitors.
DOP2024000039A (en) QUINOLINE DERIVATIVES AS ALFA4BETA7 INTEGRIN INHIBITORS
MX2017012295A (en) Formylated n-heterocyclic derivatives as fgfr4 inhibitors.
MA48798B1 (en) OZANIMOD PRODUCTION PROCESS
NZ749427A (en) Thiophene, manufacturing method thereof, and pharmaceutical application of same
MX2022004451A (en) Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases.
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
MX2021003662A (en) Aminonordecane derivative, and preparation method therefor and application thereof.
MX2022005615A (en) Tricyclic dihydroimidazopyrimidone derivative, preparation method therefor, pharmaceutical composition and use thereof.
TN2016000491A1 (en) Carboxamide derivatives.
MX2022004450A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases.
MX2021012105A (en) Pyrrole compounds.
WO2020016847A3 (en) Purification process for preparation of eribulin and intermediates thereof
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
EA201891682A1 (en) AZACYCLIC AMID DERIVATIVE, METHOD FOR ITS PREPARATION AND PHARMACEUTICAL APPLICATION
AR120727A1 (en) PHARMACEUTICAL COMPOSITION THAT COMPRISES BPI-7711 AND METHOD OF PREPARATION OF THE SAME
CO2022008616A2 (en) Oral pharmaceutical composition comprising carbamate compound and method of preparation therefor

Legal Events

Date Code Title Description
FB Suspension of granting procedure